Sirolimus oral ulcer with Cedecea davisae superinfection

Transplant Infectious Disease

Volumn 12, Issue 5, 2010, Pages 446-450

  Mawardi, H ^a   Pavlakis, M ^b   Mandelbrot, D ^b   Woo, S B ^a  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cedecea davisae; Oral ulcer; Renal transplantation; Sirolimus

Indexed keywords

ALENDRONIC ACID; AMOXICILLIN; AMPICILLIN; ATORVASTATIN; BASILIXIMAB; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; GLIPIZIDE; LEVOFLOXACIN; METOPROLOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; RAMIPRIL; RAPAMYCIN; STEROID; TACROLIMUS; VALACICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BONE MARROW SUPPRESSION; CASE REPORT; CEDECEA DAVISAE; DRUG WITHDRAWAL; ENTEROBACTERIACEAE; HUMAN; HYPERLIPIDEMIA; KIDNEY TRANSPLANTATION; MALE; MOUTH ULCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SUPERINFECTION; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ORAL ULCER; SIROLIMUS; SUPERINFECTION;

EID: 78650472758     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00514.x     Document Type: Article

References (26)

1. Grimont PAD, Grimont F, Farmer JJ III, Asbury MA. Cedecea davisae gen. nov, sp. nov. Cedecea lapagie sp. nov, new Enterobacteriaceae from clinical specimens. Int J Syst Bacteriol 1981; 31: 317-326.
2. Bae BH, Sureka SB, Ajamy JA. Enteric group 15 (Enterobacteriaceae) associated with pneumonia. J Clin Microbiol 1981; 14 (5): 596-597.
3. Farmer JJ III, Sheth NK, Hudzinski JA, Rose HD, Asbury MF. Bacteremia due to Cedecea neteri sp. nov. J Clin Microbiol 1982; 16 (4): 775-778.
4. Bae BH, Sureka SB. Cedecea davisae isolated from scrotal abscess. J Urol 1983; 130 (1): 148-149.
5. Hansen MW, Glupczynski GY. Isolation of an unusual Cedecea species from a cutaneous ulcer. Eur J Clin Microbiol 1984; 3 (2): 152-153.
6. Perkins SR, Beckett TA, Bump CM. Cedecea davisae bacteremia. J Clin Microbiol 1986; 24 (4): 675-676.
7. Coudron P, Markowitz SM. Cedecea lapagei isolated from lung tissue. Clin Microbiol Newslett 1987; 9 (21): 171-172.
8. Aguilera A, Pascual J, Loza E, et al. Bacteraemia with Cedecea neteri in a patient with systemic lupus erythematosus. Postgrad Med J 1995; 71 (833): 179-180.
9. Davis O, Wall BM. "Broom straw peritonitis" secondary to Cedecea lapagei in a liver transplant recipient. Perit Dial Int 2006; 26 (4): 512-513.
10. Dalamaga M, Pantelaki M, Karmaniolas K, Matekovits A, Daskalopoulou K. Leg ulcer and bacteremia due to Cedecea davisae. Eur J Dermatol 2008; 18 (2): 204-205.
11. Yetkin G, Ay S, Kayabas U, Gedik E, Gucluer N, Caliskan A. [A pneumonia case caused by Cedecea lapagei]. Mikrobiyol Bul 2008; 42 (4): 681-684.
12. Dalamaga M, Karmaniolas K, Arsenis G, et al. Cedecea lapagei bacteremia following cement-related chemical burn injury. Burns 2008; 34 (8): 1205-1207.
13. Farmer JJ 3rd, Davis BR, Hickman-Brenner FW, et al. Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens. J Clin Microbiol 1985; 21 (1): 46-76.
14. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59 (1): 3-16.
15. Egbuna OI, Davis RB, Chudinski R, et al. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation. Transplantation 2009; 88 (5): 684-692.
16. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67 (7): 1036-1042.
17. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000; 69 (10): 2085-2090.
18. Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80 (3): 303-309.
19. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351 (26): 2715-2729.
20. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71 (2): 271-280.
21. Van Gelder T, Ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75 (6): 788-791.
22. Warino L, Libecco J. Cutaneous effects of sirolimus in renal transplant recipients. J Drugs Dermatol 2006; 5 (3): 273-274.
23. Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79 (4): 476-482.
24. Mahalati K, Kahan BD. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine a combination therapy. Transplant Proc 2001; 33 (7-8): 3232-3233.
25. Castroagudin JF, Molina E, Tome S, Otero E, Rodriguez M, Varo E. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence. Transplant Proc 2009; 41 (3): 1003-1004.
26. Pande BN, Krysinska-Traczyk E, Prazmo Z, Skorska C, Sitkowska J, Dutkiewicz J. Occupational biohazards in agricultural dusts from India. Ann Agric Environ Med 2000; 7 (2): 133-139.